Highlighted during a previous discussion detailed in "Pharma's strategy, Part II: The suing game," Abbott was revealed to have used non-enhancing reformulations to unfairly hold on to market share despite patent expiries on the active...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)